2-氯-6-甲基-9H-嘌呤 | 1681-19-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 中文名称: 2-氯-6-甲基-9H-嘌呤
• 英文名称: 2-chloro-6-methylpurine
• 英文别名: 2-Chlor-6-methyl-purin；2-chloro-6-methyl-9H-purine；2-chloro-6-methyl-7H-purine
• CAS: 1681-19-2
• 化学式: C₆H₅ClN₄
• mdl: MFCD09756840
• 分子量: 168.585
• InChiKey: GSWWRXJYHSJFHJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  54.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335

反应信息

• 作为反应物：
  描述：

  2-氯-6-甲基-9H-嘌呤 在 potassium amide 作用下， 以 氨 为溶剂， 反应 70.0h， 以10%的产率得到6-甲基嘌呤
  参考文献：
  名称：

  The SNANRORC mechanism. 27. Occurrence of the SNANRORC mechanism in the amination of 2-substituted purines with potassium amide in liquid ammonia

  摘要：

  DOI：

  10.1021/jo01303a004
• 作为产物：
  描述：

  4-氨基-2-氯-6-甲基-5-硝基嘧啶 在 甲醇 、 乙酸酐 、 镍 作用下， 生成 2-氯-6-甲基-9H-嘌呤
  参考文献：
  名称：

  Potential Purine Antagonists. XVI. Preparation of Some 2-, 6- and 8-Methylpurines¹

  摘要：

  DOI：

  10.1021/ja01510a044

文献信息

• [EN] COMPOUNDS AS INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR<br/>[FR] COMPOSÉS EN TANT QU'INHIBITEURS DU FACTEUR INHIBITEUR DE LA MIGRATION DES MACROPHAGES
  申请人：IMMUNOPHAGE BIOMEDICAL CO LTD

  公开号：WO2020186220A1

  公开（公告）日：2020-09-17

  The present invention provides compounds of Formula (I) shown above and their pharmaceutically acceptable salt, solvates, isomers, or prodrugs, as well as pharmaceutical compositions containing these compounds. Also provided by the invention is a method for treating a disorder mediated by macrophage migration inhibitory factor in a subject, comprising administering to the subject in need thereof a compound or a pharmaceutical composition of this invention.

  本发明提供了上述公式(I)所示的化合物及其药用可接受的盐、溶剂化物、异构体或前药，以及含有这些化合物的药物组合物。本发明还提供了一种用于治疗由巨噬细胞迁移抑制因子介导的疾病的方法，包括向需要治疗的对象施用本发明的化合物或药物组合物。
• 1H-PYRAZOLO[3,4-D]PYRIMIDINE, PURINE, 7H-PURIN-8(9H)-ONE, 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE, AND THIENO[3,2-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES
  申请人：Zask Arie

  公开号：US20090192176A1

  公开（公告）日：2009-07-30

  The invention relates to 1H-pyrazolo[3,4-d]pyrimidine, purine, 7H-purin-8(9H)-one, 3H-[1,2,3]triazolo[4,5-d]pyrimidine, and thieno[3,2-d]pyrimidine compounds, compositions comprising the compounds, and methods for making and using the compounds.

  这项发明涉及1H-吡唑并[3,4-d]嘧啶，嘌呤，7H-嘌呤-8(9H)-酮，3H-[1,2,3]三唑并[4,5-d]嘧啶和噻吩[3,2-d]嘧啶化合物，包含这些化合物的组合物，以及制备和使用这些化合物的方法。
• [EN] TRICYCLIC HETEROCYCLES USEFUL AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS<br/>[FR] HÉTÉROCYCLES TRICYCLIQUES UTILES COMME INHIBITEURS DE LA DIPEPTIDYL PEPTIDASE IV
  申请人：SCHERING CORP

  公开号：WO2012078448A1

  公开（公告）日：2012-06-14

  The present invention is directed to novel tricyclic heterocycles of structural formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved. I

  本发明涉及具有结构式I的新型三环杂环化合物，这些化合物是二肽基肽酶-IV酶的抑制剂，对治疗或预防二肽基肽酶-IV酶参与的疾病具有用处，如糖尿病，特别是2型糖尿病。该发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在预防或治疗二肽基肽酶-IV酶参与的疾病中的使用。
• [EN] CYSTEINE BINDING COMPOSITIONS AND METHODS OF USE THEREOF<br/>[FR] COMPOSITIONS DE LIAISON À LA CYSTÉINE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：UNIV VIRGINIA PATENT FOUNDATION

  公开号：WO2021016263A1

  公开（公告）日：2021-01-28

  Purine-derived covalent probes (e.g., halo or di-halo-substituted purine based covalent probes) and related ligands are described. The compounds can be used to identify reactive nucleophilic amino acid residues, such as reactive cysteine residues, in proteins and to modify the activity of proteins with reactive nucleophilic amino acid residues (e.g., reactive cysteine residues) via the formation of protein adducts comprising the ligands. Modified proteins prepared from the probes and ligands are also described.

  描述了嘌呤衍生的共价探针（例如，基于卤素或二卤代嘌呤的共价探针）和相关配体。这些化合物可用于识别蛋白质中的反应性亲核氨基酸残基，例如反应性半胱氨酸残基，并通过形成包含配体的蛋白质加合物来修改具有反应性亲核氨基酸残基（例如，反应性半胱氨酸残基）的蛋白质的活性。还描述了从探针和配体制备的修饰蛋白质。
• [EN] COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF DISEASE<br/>[FR] COMPOSÉS ET COMPOSITIONS POUR LE TRAITEMENT D'UNE MALADIE
  申请人：SPEROVIE BIOSCIENCES INC

  公开号：WO2017123766A1

  公开（公告）日：2017-07-20

  This invention relates to compounds (e.g., a compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt thereof) and compositions for use in modulating PDE4 as well as the preventing and treating a PDE4-mediated disease in a subject.

  这项发明涉及化合物（例如，式（I）或式（II）的化合物或其药用可接受的盐）和用于调节PDE4的组合物，以及用于预防和治疗受试者中的PDE4介导疾病的组合物。